Analysts Viewpoint
CLSD Stock Sees Decline of Approximately -2.24% in Last Five Days
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Menu
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Clearside Biomedical Inc’s filing revealed that its Director Thorp Clay acquired Company’s shares for reported $13800.0 on Feb 24 ’25.